Direct-to-consumer virtual health company Ro announced Monday it’s $200 million Series C funding round. With these additional funds, the company is now valued at $1.5 billion.
The existing investor, General Catalyst, led the round with participation from FirstMark Capital, Torch, SignalFire, TQ Ventures, Initialized Capital, 3L, BoxGroup and the Chernin Group. Ro has raised $376 million since its...
Ro, a direct-to-consumer virtual health startup best known for its sexual health products, is dipping into the dermatology space. Patients will now be able to use the service for prescription products that include eczema treatment, medical-grade antiperspirant, and prescription dandruff shampoo.
The company will also be rolling out a “nightly defense skincare” that is a custom prescription...
Direct-to-consumer virtual health company Ro is now offering allergy care. The launch means that users of Roman and Rory will be able to get prescription allergy medications through the platform’s telemedicine model.
While the company said that the new service will not be treating food allergies or uncontrolled asthma, it will cover seasonal allergies, including conditions like hay fever. ...
Ro — the company which made its mark with a men’s health platform focused on erectile dysfunction called Roman — has landed an additional $85 million in Series B financing, according to a source at TechCrunch.
When MobiHealthNews reached out, the company declined to comment on this funding.
WHAT THEY DO
Ro made a name for itself in the digital health world with its online platform that...
Mail-order menopause treatment. Online men’s and women’s health platform Ro is expanding its services with the launch of a new platform for women experiencing menopause.
Called Rory, the platform treats for hot flashes, vaginal dryness, sleep deprivation and other symptoms of menopause, while also seeking to educate users on their personal health. Much like Ro’s other offerings, the service kicks...
